ClinicalTrials.gg
RecruitingNCT05325437ELSDLUpdated May 30, 2025

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients

An interventional study of Laparoscopic splenectomy and azygoportal disconnection in Cirrhosis, Liver, Splenectomy; Status and Portal Hypertension, sponsored by Northern Jiangsu People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Northern Jiangsu People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital — 8 open to participants now, 8 under way, none of them phase 3. Liver Cirrhosis · Northern Jiangsu People's Hospital.

Started
2022
with 5 others
No phase
5 of 11
4 open now
Registered
1st of 11
by date

Among the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital, this one is one of 6 that started in 2022, is one of 5 with no phase, and was the 1st registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

8 of the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital, or all of them as a file.
02

Study summary

In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative liver reserve function and improve patient prognosis.

Read the detailed description

The patients were enrolled according to the research criteria, and collected the general basic information of the patients. After the preoperative preparation was perfected, the same surgical team performed laparoscopic splenectomy and azygoportal disconnection, and the same nursing team performed the nursing after the operation. Then, patients received a unified treatment plan after surgery, including medication, other treatments and follow-up. During the treatment, the liver reserve function related indicators of the patients were monitored before surgery, 3, 6, 12 and 24 months after surgery, including TBIL, DBIL, ALB, ALT, INR, PT, Child-Pugh, ascites, prealbumin, ICG-K, ICG-R 15 and ICG-T/2.

03

Conditions studied

  • Cirrhosis, Liver
  • Splenectomy; Status
  • Portal Hypertension

Keywords

  • Cirrhosis
  • Splenectomy
  • Azygoportal disconnection
  • Laparoscopy
  • Liver Reserve Function
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
  • Splenomegaly with secondary hypersplenism
  • gastroesophageal variceal bleeding
  • to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Hepatocellular carcinoma or any other ,
  • grade C
  • Recent peptic ulcer disease
  • History of Hemorrhagic stroke
  • Pregnancy.
  • Uncontrolled Hypertension
  • (HIV) infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Laparoscopic splenectomy and azygoportal disconnection

    Procedure: Laparoscopic splenectomy and azygoportal disconnection

Interventions

  • ProcedureLaparoscopic splenectomy and azygoportal disconnection

    The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.

06

What researchers measure

Primary outcomes

  1. Liver reserve function ICG-K at 3 months after surgery.

    The level of liver reserve function ICG-K at 3 months after surgery.

    Time frame: 3 months

  2. Liver reserve function ICG-K at 6 months after surgery.

    The level of liver reserve function ICG-K at 6 months after surgery.

    Time frame: 6 months

  3. Liver reserve function ICG-K at 12 months after surgery.

    The level of liver reserve function ICG-K at 12 months after surgery.

    Time frame: 12 months

  4. Liver reserve function ICG-K at 24 months after surgery.

    The level of liver reserve function ICG-K at 24 months after surgery.

    Time frame: 24 months

  5. Liver reserve function ICG-R 15 at 3 months after surgery.

    The level of liver reserve function ICG-R 15 at 3 months after surgery.

    Time frame: 3 months

  6. Liver reserve function ICG-R 15 at 6 months after surgery.

    The level of liver reserve function ICG-R 15 at 6 months after surgery.

    Time frame: 6 months

  7. Liver reserve function ICG-R 15 at 12 months after surgery.

    The level of liver reserve function ICG-R 15 at 12 months after surgery.

    Time frame: 12 months

  8. Liver reserve function ICG-R 15 at 24 months after surgery.

    The level of liver reserve function ICG-R 15 at 24 months after surgery.

    Time frame: 24 months

  9. Liver reserve function ICG-T/2 at 3 months after surgery.

    The level of liver reserve function ICG-T/2 at 3 months after surgery.

    Time frame: 3 months

  10. Liver reserve function ICG-T/2 at 6 months after surgery.

    The level of liver reserve function ICG-T/2 at 6 months after surgery.

    Time frame: 6 months

  11. Liver reserve function ICG-T/2 at 12 months after surgery.

    The level of liver reserve function ICG-T/2 at 12 months after surgery.

    Time frame: 12 months

  12. Liver reserve function ICG-T/2 at 24 months after surgery.

    The level of liver reserve function ICG-T/2 at 24 months after surgery.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ding S, Zhou LX, Gao TM, Shi ZB, Chen C, Jin SJ, Zhang C, Zhou BH, Bai DS, Jiang GQ. Effects of laparoscopic splenectomy and azygoportal disconnection on liver reserve function for cirrhosis patients: a 1-year prospective study. Surg Endosc. 2026 Aug 7. doi: 10.1007/s00464-026-13274-7. Online ahead of print. PubMed 42566007 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jul 2025, 40 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 40 months is above that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2022
First posted
Apr 13, 2022
StartActual
Mar 1, 2022
Primary completionEst.
Jul 31, 2025
CompletionEst.
Jul 31, 2025
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05325437
Lead sponsor
Northern Jiangsu People's Hospital
Responsible party
Guo-Qing Jiang (Clinical Professor, Northern Jiangsu People's Hospital) — Principal investigator
First posted
Apr 13, 2022
Start date
Mar 1, 2022
Primary completion
Jul 31, 2025 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
May 30, 2025

Study contacts

Guo-Qing Jiang, MD
Contact
jgqing2003@hotmail.com
+8651487373272
Dou-Sheng Bai, MD
Contact
bdsno1@hotmail.com
+8651487373372
Guo-Qing Jiang, MD
study chair · Clinical Medical College of Yangzhou University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion